CanSino Biologics
Latest round
- Series E
Last raised
- Apr 2017
Total raised
- $136M
Investors
- 6
About CanSino Biologics
Founded in 2009 and based in Tianjin, China, CanSino Biologics Inc. operates as a biotechnology company that provides solutions to prevent communicable and infectious diseases. In 2012, the company completed the construction of a pilot plant designed to meet GMP standards. In 2018, it completed construction of a commercial production center. In 2019, the company was listed on the Hong Kong Stock Exchange. Its stock code is 6185. In 2020, CanSino Biologics Inc. was listed on the Shanghai Stock Exchange. Its stock code is 688185. The firm has vaccine industry bases in Tianjin and Shanghai, with a construction area of over 200,000 square meters. The company's main products include the new coronavirus vaccine (type 5 adenovirus vector) Keweisha®, the new crown vaccine Kewisha® Wuyou®, the quadrivalent meningococcal conjugate vaccine ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 vector) Mann Haixin® and bivalent meningococcal conjugate vaccine group A and group C meningococcal polysaccharide conjugate vaccine (CRM197 carrier) Minasi®, etc. Its products are used in diseases such as COVID-19, Ebola virus disease, tuberculosis, meningitis, and diphtheria.
Who invested in CanSino Biologics
6 investors across 4 rounds
See all investors in CanSino Biologics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CanSino Biologics
Who invested in CanSino Biologics?
CanSino Biologics has 6 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CanSino Biologics raised?
CanSino Biologics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did CanSino Biologics last raise money?
CanSino Biologics's most recent round on record is a Series E, in Apr 2017.
What does CanSino Biologics do?
Founded in 2009 and based in Tianjin, China, CanSino Biologics Inc.
Where is CanSino Biologics headquartered?
CanSino Biologics is headquartered in Tianjin, China.
Which VCs invest in companies like CanSino Biologics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at CanSino Biologics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series E
Raising like CanSino Biologics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.